Company Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 1997 |
| IPO Date | Jan 23, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Moshe Arkin |
Contact Details
Address: 7 Golda Meir Street, Weizmann Science Park Ness Ziona, 7403650 Israel | |
| Phone | 972 8 931 3433 |
| Website | sol-gel.com |
Stock Details
| Ticker Symbol | SLGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001684693 |
| CUSIP Number | M8694L137 |
| ISIN Number | IL0011417206 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Moshe Arkin | Chief Executive Officer and Executive Chairman |
| Tamar Fishman Jutkowitz | Vice President and General Counsel |
| Eyal Ben-Or | Chief Financial Officer |
| Dr. Itzik Yosef | Chief Operating Officer |
| Michael Glezin | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | 424B3 | Prospectus |
| May 23, 2025 | 6-K | Report of foreign issuer |
| May 22, 2025 | 6-K | Report of foreign issuer |
| May 8, 2025 | EFFECT | Notice of Effectiveness |
| May 8, 2025 | 424B3 | Prospectus |
| May 8, 2025 | 6-K/A | Filing |
| May 5, 2025 | 6-K | Report of foreign issuer |
| May 2, 2025 | UPLOAD | Filing |
| Apr 30, 2025 | EFFECT | Notice of Effectiveness |
| Apr 30, 2025 | SCHEDULE 13D/A | Filing |